A Randomized, Double-blind, Placebo-controlled, Single and Multiple Rising Dose Study to Explore the Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of SB26 in Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
At a glance
- Drugs SB-26 (Primary)
- Indications Pancreatitis
- Focus Adverse reactions
- Sponsors Samsung Bioepis
- 02 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 New trial record